(Q34595727)

3 August 2017

title

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues (English)

1 reference

3 August 2017

Lata T Gooljarsingh

1

1 reference

3 August 2017

Christine Fernandes

2

1 reference

3 August 2017

Kang Yan

3

1 reference

3 August 2017

Hong Zhang

4

1 reference

3 August 2017

Michael Grooms

5

1 reference

3 August 2017

Kyung Johanson

6

1 reference

3 August 2017

Robert H Sinnamon

7

1 reference

3 August 2017

Robert B Kirkpatrick

8

1 reference

3 August 2017

John Kerrigan

9

1 reference

3 August 2017

Tia Lewis

10

1 reference

3 August 2017

Marc Arnone

11

1 reference

3 August 2017

Alastair J King

12

1 reference

3 August 2017

Zhihong Lai

13

1 reference

3 August 2017

Robert A Copeland

14

1 reference

3 August 2017

Peter J Tummino

15

1 reference

3 August 2017

language of work or name

English

0 references

publication date

9 May 2006

1 reference

Proceedings of the National Academy of Sciences of the United States of America

3 August 2017

published in

1 reference

3 August 2017

volume

103

1 reference

3 August 2017

issue

20

1 reference

3 August 2017

page(s)

7625-7630

1 reference

Heat shock proteins and acute leukemias

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Hsp90 chaperones wild-type p53 tumor suppressor protein

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Therapeutic and diagnostic implications of Hsp90 activation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Hsp90 inhibitors as novel cancer chemotherapeutic agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Stimulation of the weak ATPase activity of human hsp90 by a client protein

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Structure and in vivo function of Hsp90.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

The assembly of progesterone receptor-hsp90 complexes using purified proteins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0602650103

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0602650103

Development of a fluorescence polarization assay for the molecular chaperone Hsp90.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0602650103

17AAG: low target binding affinity and potent cell activity--finding an explanation

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1458618

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists

27 October 2018

1 reference

12 December 2020

Synthesis of novel fluorescent probes for the molecular chaperone Hsp90

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts

1 reference

12 December 2020

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

12 December 2020

Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0602650103

1 reference

3 August 2017

0 references

1 reference

3 August 2017

1 reference